CardiaTec Secures $6.5 Million to Combat Cardiovascular Diseases
CardiaTec, a forward-thinking TechBio company based in Cambridge, England, UK, has garnered significant attention after successfully raising $6.5 million in seed funding. This capital infusion was primarily led by Montage Ventures, with additional support from notable investors including Laidlaw Scholars Ventures, Apex Ventures, and Continuum Health Ventures. The funding round also attracted individual contributions from esteemed professionals such as Dr. Maximilien Levesque, the CEO and Co-Founder of Aqemia, and Naheed Kurji, the former President of Recursion Pharmaceuticals Canada and the CEO & Founder of Cyclica. By securing such backing, CardiaTec is poised to make great strides in understanding and therapeutically addressing cardiovascular diseases.
The company was co-founded by a talented trio: Prof.
Namshik Han, who serves as the Chief Technology Officer, Thelma Zablocki in the role of Chief Operating Officer, and Raphael Peralta, the Chief Executive Officer. Their combined expertise is instrumental in driving CardiaTec's mission of decoding the complex biology behind cardiovascular disease through innovative computational methods. The funds raised will be utilized to expand their platform capabilities and advance proprietary drug targets towards wet lab validation, an essential step in the drug development process.
One of the key strategies employed by CardiaTec involves leveraging extensive multi-omics human data to navigate the intricate biology related to cardiovascular disease. To this end, the company is developing a unique human heart tissue multi-omics dataset, which is expected to provide invaluable insights into the disease landscape. Additionally, CardiaTec maintains a robust network of over 65 hospitals across the United States and the United Kingdom, screening patients around the clock to facilitate the bespoke collection of human hearts for their data generation efforts. This meticulous approach, combined with the strategic insights of their Scientific Advisory Board, including Dr. Joseph Lehár, will allow CardiaTec to identify novel and more targeted therapeutic options to combat cardiovascular conditions effectively.
They've invested in CardiaTec
Get to know these Biotech investors
Click here for a full list of 6,908+ startup investors in the UK